Chromogranin A and neurone‐specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration‐resistant prostate cancer

Abstract

We found that CgA and NSE elevation during the first 3 months of AA treatment and elevated baseline CgA and NSE levels were independent prognostic factors for OS, rPFS and PSA-PFS in patients with mCRPC treated with AA. This suggests that serial CgA and NSE evaluation may help clinicians in distinguishing patients with mCRPC who would obtain the best survival benefit from AA treatment.